Shibo Jiang
Head
Complement Biology
Complement Biology, New York Blood Center
United States of America
Biography
"The research focus of the Laboratory of Viral Immunology is on the development of antiviral therapeutic agents and vaccines for the treatment and prevention of HIV infection/AIDS and other emerging and remerging infectious diseases caused by severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza viruses, as well as the blood transfusion-related viruses, including zika virus (ZIKV) and West Nile virus (WNV). Dr. Shibo Jiang is a pioneer in the field of viral fusion/entry inhibitors. His research focuses on development of therapeutics/vaccines against HIV, SARS-CoV, MERS-CoV, and avian influenza viruses. He has published 311 peer-reviewed papers, awarded 18 US patents, and served as editorial board members for 8 journals."
Research Interest
Virology
Publications
-
Ouyang Y, Yin Q, Li W, Li Z, Kong D, et al. (2017) Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Sci Rep 7: 6222.
-
Yu Y, Deng YQ, Zou P, Wang Q, Dai Y, et al. (2017) A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat Commun 8: 15672.
-
Du L, Zhou Y, Jiang S (2017) The latest advancements in Zika virus vaccine development. Expert Rev Vaccines 7: 1-4.
